ABOUT US

Our Purpose

PSK Bio is dedicated to increasing treatment possibilities for patients by developing targeted in vivo RNA therapies.

Our core platform technology involves proprietary targeted exosome particles, which consist of exosome particles that are genetically modified on their outer surface with recombinant protein binders (such as monoclonal antibodies, scFvs, and targeting peptides). These particles are designed to deliver payloads, including nucleic acid-based drugs or gene editing tools, capable of reprogramming specific cell types in vivo.

Our Engineered exosome platform is made up of three components:

Exosome delivery vehicle

PSK Bio's proprietary exosome delivery system is a non-viral platform designed to enable drug delivery that is low in immunogenicity, safe and repeatable in vivo.

Cell and tissue specific targeted binding

Antibodies, antibody fragments, and targeting peptides are engineered onto the exosome surface to produce targeted exosomes for the effective delivery of disease-specific drugs.

Disease-specific payloads

mRNA encoding chimeric antigen receptors (CARs), small RNA, gene editing mechanisms, and other therapeutic proteins.